Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.
Three hundred and forty-seven subjects at risk for herpes genitalis were vaccinated with Skinner vaccine, NFUAc.HSV1.(S-MRC5), and were followed for an average duration of 2 years representing a total consortship of 664.4 years. Based on survey information obtained during this consortship, there were estimated to be 3076 recurrences which summated to 3.5 years total duration of disease and comprised at least 6794 lesions; there were an estimated 51997 episodes of intercourse including at least 241 episodes of unprotected intercourse in the presence of herpetic lesions. The rate of contraction of herpes genitalis was 6 of 54 consorts (11.1%) who received one vaccination and 7 of 293 (2.4%) who received two, three of four vaccinations. There was no evidence of physical or psychological side effects from vaccination.
Skinner
G R
GR
Department of Medical Microbiology, Medical School, University of Birmingham, Great Britain.
Fink
C
C
Melling
J
J
Wiblin
C
C
Thornton
B
B
Hallworth
J
J
Gardner
W
W
McLeish
P
P
Hartley
C
C
Buchan
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D002460:Cell Line; D004279:DNA, Viral / Q000302:isolation & purification / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D006558:Herpes Genitalis / Q000453:epidemiology / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007115:Immunization Schedule; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012307:Risk Factors; D012725:Sexual Behavior; D012747:Sexual Partners; D015164:Vaccines, Inactivated; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology
D004279:DNA, Viral; D015164:Vaccines, Inactivated; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C039447:glycoprotein D, Human herpesvirus 1